Delivery Order SPE2DB20D3103-SPE2DB22FP8N2

Award Date 9/12/22
Potential Completion Date 10/3/22
Potential Value $4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,423.90 Firm Fixed Price Delivery Order contract, which runs through February 2025, is for the supply of Envarsus XR 4 mg tablets. The award is not associated with a set-aside program. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,230.68 firm fixed-price delivery order is for the supply of Envarsus XR 4 mg tablets. The contract has a period of performance through June 25, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, from the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,465.68, is for the delivery of Envarsus XR 1 mg tablets. The award has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,711.95 firm fixed-price delivery order is for the supply of ENVARSUS XR 4 MG TABLET 100S, a pharmaceutical product. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $4,845.99 firm fixed price delivery order is for the supply of Envarsus XR 4 mg tablets. The contract has an ultimate completion date of July 12, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,379.55 firm-fixed-price delivery order is for the supply of Envarsus XR 0.75 mg tablets, with a period of performance through October 30, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 with the DLA Troop Support Medical for delivering a broad range of medical...
This federal contract award, valued at $1,465.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the delivery of Envarsus XR 1 mg tablets in quantities of 30, with a period of performance through April 30, 2024. This is a firm-fixed-price delivery order contract, and there is no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The $1,216.11 firm-fixed-price delivery order is for the pharmaceutical product Envarsus XR 1 mg tablet, with a completion date of July 8, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Envarsus XR 4 mg tablets. The contract, valued at $1,615.33, is a firm-fixed price delivery order with a completion date of November 5, 2024. Amerisourcebergen has been awarded multiple indefinite delivery contracts (IDCs) with the DLA Troop Support Medical and the Department of Justice Federal Bureau of Investigation, valued up to...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract, valued at $8,076.65, is for the delivery of Envarsus XR 4 mg tablets over a period ending on July 30, 2024. This contract is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB22FP8N2
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,027.44 firm fixed-price delivery order is for Envarsus XR 1 mg tablets and does not have a set-aside designation, indicating open competition.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also has a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024 covering similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 1:18 PM